株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

再発性急性骨髄性白血病:世界の治験動向

Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 300505
出版日 ページ情報 英文 431 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
再発性急性骨髄性白血病:世界の治験動向 Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016
出版日: 2016年07月29日 ページ情報: 英文 431 Pages
概要

当レポートでは、再発性急性骨髄性白血病治療薬に関する治験の最新動向について分析しており、主要7カ国 (G7) および新興7カ国 (E7) における治験件数、被験者数、有望なスポンサー、治験に携わっている主な企業や機関、有望な薬剤の情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:癌治療薬の治験における再発性急性骨髄性白血病の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における再発性急性骨髄性白血病の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

再発性急性骨髄性白血病治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3632CTIDB

GlobalData's clinical trial report, "Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016" provides an overview of Relapsed Acute Myeloid Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Acute Myeloid Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Relapsed Acute Myeloid Leukemia
      • Jul 20, 2016: Actinium Pharmaceuticals Highlights Successful Investigator Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial
      • Jul 12, 2016: ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia
      • Jul 06, 2016: Actinium Pharmaceuticals to Sponsor Investigator Meeting for Pivotal Phase 3 SIERRA Trial for Iomab-B
      • Jun 29, 2016: Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA Trial
      • Jun 13, 2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1
      • Jun 09, 2016: Actinium Announces Strong Presence at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
      • Jun 06, 2016: GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
      • Jun 06, 2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress
      • Jun 06, 2016: Tolero Pharmaceuticals To Present Update On TP-1287 Program At 2016 EHA Congress
      • May 31, 2016: Syros Pharmaceuticals Announces FDA Acceptance of IND to Advance SY-1425 Into Phase 2 Clinical Trial
      • May 19, 2016: Astellas Oncology Announces Data on gilteritinib to be Presented at 2016 ASCO Annual Meeting
      • May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top